Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Pu
Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NAS: ESPR) , a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the underwriters of its recently completed initial public offering (IPO) have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments. The sale of the additional shares closed on July 11, 2013. Including proceeds from the sale of the additional shares, the net proceeds to Esperion from the IPO are expected to be $72.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion.
Credit Suisse and Citigroup acted as joint book-running managers for the offering. JMP Securities and Stifel acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2013. Copies of the final prospectus relating to the offering may be obtained by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing email@example.com; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at firstname.lastname@example.org, or by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
KEYWORDS: United States North America Michigan
The article Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.